InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,986.40
(
0.30%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
0.00%
)
Bitcoin
59,868.13
(
-1.17%
)
Post# of 253124
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

go seek

Send PM Follow Ignore
Followers 21
Posts 4821
Boards Moderated 0
Alias Born 06/24/2006

go seek

Member Level

Re: ThomasS post# 48434

Tuesday, 06/12/2007 10:28:41 AM

Tuesday, June 12, 2007 10:28:41 AM

Post# of 253124
IDIX.. apparently BS was upset on the ITT basis results @ 12 weeks.

the fact that there were no drug drug interaction and response w/ NM283 is dose related (and 200 mg was used here) says there is room for improvement...

most importantly the triple beat the SoC @ all points thru the trial

obviously there is a long way to go... but the pathway for NM283 is clearer today. AND IMO upgrades will follow...





The creation of a thousand forests is in one acorn.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up